Is the path to the future clear or paved with many obstacles?

With the 2020 JP Morgan Healthcare conference coming up next week, I thought this would be a great time to sit down and lay out some provocative concepts in terms of where we might be headed in oncology R&D for the next decade.

Every couple of years we tackle the critical topic of looking in the crystal ball on the future of cancer research to look at where oncology R&D pipelines are potentially headed.

Obviously it’s not an easy task compared to the value of hindsight in looking back at the last decade and describing what’s already occurred.

Here we highlight six key strategic elements that may need to be considered in terms of future R&D directions and considerations.

Curious to find out more about our oncology coverage and get a heads up on additional insights from our latest analysis and commentary? Subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers